| Literature DB >> 19495967 |
Marie Gottschalk1, Anders Bach, Jakob Lerche Hansen, Povl Krogsgaard-Larsen, Anders S Kristensen, Kristian Strømgaard.
Abstract
The PDZ domain mediated interaction between the NMDA receptor and its intracellular scaffolding protein, PSD-95, is a potential target for treatment of ischemic brain diseases. We have recently developed a number of peptide analogues with improved affinity for the PDZ domains of PSD-95 compared to the endogenous C-terminal peptide of the NMDA receptor, as evaluated by a cell-free protein-protein interaction assay. However, it is important to address both membrane permeability and effect in living cells. Therefore a bioluminescence resonance energy transfer (BRET) assay was established, where the C-terminal of the NMDA receptor and PDZ2 of PSD-95 were fused to green fluorescent protein (GFP) and Renilla luciferase (Rluc) and expressed in COS7 cells. A robust and specific BRET signal was obtained by expression of the appropriate partner proteins and subsequently, the assay was used to evaluate a Tat-conjugated peptide for its ability to disrupt the PSD-95/NMDA receptor interaction in living cells.Entities:
Mesh:
Substances:
Year: 2009 PMID: 19495967 DOI: 10.1007/s11064-009-9998-4
Source DB: PubMed Journal: Neurochem Res ISSN: 0364-3190 Impact factor: 3.996